Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted May 21, 2007
Bariatric surgery-- when all else fails in diabetic patients
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Member Program Contributor
Bariatric surgery is a viable option for in properly selected, well-motivated, desperate patients with diabetes.
Posted May 21, 2007
SoloStar may become the new star in insulin administration
Analysis of: FDA Approves Lantus SoloStar(R) A New Prefilled Disposable Insulin Pen For Use With LANTUS(R) In People With Type 1 And Type 2 Diabetes | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Pen delivery of insulin is the gold standard. SoloStar is as least as valuable a tool as the FlexPen.  The SoloStar will impact, mainly the short-acting analogue market, but should become the primary choice for Lantus administration.
Posted May 18, 2007
Already in heavy use
Analysis of: Lupin Receives US FDA Approval For Simvastatin Tablets | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Generic simvastatin is here to stay.PBMs are already substituting or asking that generic simvistatin be used. At present ,as generics, need to meet certain standards of efficacy, there should be no major issue.
Posted May 11, 2007
Kidney Transplant Outcomes may improve with Rapamycin based Immunosupression
Analysis of: Early Results Of The CellCept(R) Spare The Nephron Study Examine Kidney Function | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Interim results from "Spare the Nephron Trial" demosntrate improved outcomes with Rapamycin based immunosupression compared with Calcinuerin based therapy.   If the results hold up the trial may precipitate a shift away from the use of cyclospoin and tacrolimus based therapy in favor...
Posted May 9, 2007
Keeping it simple
Analysis of: FDA Approves Lantus SoloStar(R) A New Prefilled Disposable Insulin Pen For Use With LANTUS(R) In People With Type 1 And Type 2 Diabetes | www.medicalnewstoday.com
Author: GLG Member Program Contributor
More and more patients are now requiring Insulin therapy. With the upsurge in obesity rates, we are seeing more need for this form of therapy. Compliance is always an issue. The simpler  the method of delivery the more likely it will be used and used properly. The competitors are already there
Posted May 8, 2007
School Nurtures Our Minds, and Must Guide Us in Nurturing our Bodies as Well
Analysis of: Need To Establish School Nutrition Standards And Limit Access To Competitive Foods | www.medicalnewstoday.com
Author: GLG Member Program Contributor
The time spent in school, 7-8hrs/day, from K through 12, is powerfully formative in guiding our children's life choices.  Food is part of this calculus.  Whether the food is "junk" or nutritious, the school sets a formidable example.
Posted May 8, 2007
Fight the cells that cause the damage
Analysis of: MacroGenics and JDRF Sealed Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes | www.pharmagazette.com
Author: GLG Member Program Contributor
Anti-CD3 antibodies such as teplizumab (MGA031, hOKT3-gamma-1 (Ala-Ala)) are engineered to block the function of CD3 cells, immune T cells that orchestrate the destruction of islets. This prevents "activation" of the T cells after they have identified their target, disarming them once they are poised...
Posted May 7, 2007
One less safety concern?
Analysis of: Rosiglitazone Does Not Adversely Affect Cardiac Function in Type 2 Diabetics With Heart Failure | www.medscape.com
Author: GLG Member Program Contributor
The problem with TZD's besides cost, has been the issue of edema. This has made physicians relunctant to use them in patients with CHF. Metformin is contraindicated in that situation limiting the use of oral agents. This study gives us some reassurance that the use of Rosigitzone is safe.
Posted May 4, 2007
An added benefit
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Member Program Contributor
Bariactric surgery is no easy deal. First convince the patient and then have him or her go thru a series of exams by various specialists including psychiatry before proceding. If diabetes is there the weight loss will improve the condition. It is not a primary indication by any means.
Posted May 2, 2007
Not unexpected
Analysis of: Merck Receives Non Approvable Letter from FDA | home.businesswire.com
Author: GLG Member Program Contributor
Merck may have a reasonable drug, but safety is now a major concern with all NSAIDs. The drug needs to be really side effect free, for the FDA to consider it. This may be a case of: smack me once, shame on you, smack me twice shame on me.
Previous Page : 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Next261 to 270 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617